Could a new PET tracer reveal hidden prostate cancer activity?
NCT ID NCT05242744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radioactive tracer called [18F]FluorThanatrace (FTT) used with PET/CT scans to measure PARP-1 activity in men with metastatic prostate cancer. Up to 30 participants will have scans before and after starting a new therapy. The goal is to see if FTT can non-invasively show PARP expression, which might help guide treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]FluorThanatrace (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a better way to see PARP activity in prostate cancer tumors using a simple scan, helping doctors choose the right treatments.
What could go wrong
This is a small, early-phase imaging study with only 30 participants. The tracer may not reliably show PARP activity in all patients, and it is not a treatment itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact